

Relevance of protein nitration in brain injury: a key pathophysiological mechanism in neurodegenerative, autoimmune, or inflammatory CNS diseases and stroke

Review Article

P. Sarchielli¹, F. Galli², Ar. Floridi², Al. Floridi², and V. Gallai¹

¹Neuroscience Department, Neurological Clinic, University of Perugia, Italy

²Department of Internal Medicine, Section of Clinical and Applied Biochemistry, University of Perugia, Perugia, Italy

Received December 2, 2002

Accepted May 8, 2003

Published online August 21, 2003; © Springer-Verlag 2003

Summary. This review has focused on the evidence for the involvement of nitrative oxidation in certain neurodegenerative disorders (Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis), stroke, and inflammatory and autoimmune disorders (with particular attention devoted to multiple sclerosis).

The relationship between protein peroxidation and pathological changes observed in the above disorders has been reported. Whereas many of the findings are from studies with animal models and autaptic specimens from human patients, few data are available from cerebrospinal fluid and blood samples of the patients at different times and disease stages.

The participation of nitrative oxidation to the direct and indirect injury of neurons and other cells of the brain (i.e., oligodendrocytes, for multiple sclerosis) is clear; less evident is their relevance for the development and progression of these disorders.

Further studies should be aimed to establish the clinical and prognostic value of peroxidative markers for the CNS diseases considered. This is fundamental for the development of therapeutic interventions antagonizing nitric oxide-related species damage.

Keywords: Protein nitration – Nitrotyrosine – Neurodegenerative diseases – Inflammatory and autoimmune diseases of the central nervous system – Stroke – Pathogenic mechanisms

Introduction

Cellular stress is considered one of the pivotal mechanisms involved in the initiation and progression of neuronal cell injury underlying several central nervous system (CNS) disorders. Mediators of cellular stress and damage are reactive oxidative species (ROS) such as hydroxyl radicals (OH•), tyrosyl radicals (TyrO•) and reactive nitrogen species (RNS) including peroxynitrites (PN),

nitric oxide (NO•) and nitric dioxide (NO₂•) radicals. Their increased production together with the lack or insufficiency of antioxidant capacity have been hypothesized and at least in part demonstrated to underlie different neurodegenerative disorders. Biochemical events initiated by these reactive species can induce lipid peroxidation and protein oxidation and nitration, leading to cell damage and death by apoptosis and autophagy (Kochman et al., 2002).

In the last few years it has become evident that tyrosine and TyrO• are implicated in nitrative and oxidative events involved in neuronal death. Both can interact with ROS and RNS via radical and chain propagating reactions.

Oxidation of tyrosine by the SOD1/H₂O₂/HCO₃[–] system is the basis of major reaction pathways leading to the formation of dityrosine (DT), 3-nitrotyrosine (3-NT), NO₂-DiTyr (3-NDT) and other higher oxidation products. In particular, 3-NDT has been proposed as a reliable marker of both oxidation/nitration of Tyr *in vivo*. However, the relationship between 3-NT bound to proteins and free 3-NT is still unknown, as well as its biological and pathological relevance (Halliwell, 1997; Zhang et al., 2000; see also Duncan, this volume).

Nitration of Tyr residues has important consequences for the cell, by inducing structural (i.e., in neurons it may disrupt neurofilaments) and enzymatic alterations (Beckman and Koppenol, 1996); and because it inhibits tyrosine

phosphorylation and thereby interferes with important signaling pathways (Van der Vliet et al., 1995).

Elderly people are more susceptible to oxidative and nitrative stress and damage than the young. An age-related impairment for recognition and turnover of modified cell components, particularly proteins, exists and antioxidant mechanisms are also less efficient (Gracy et al., 1999). Hence, oxidative/nitrative damage could play a causative role in many chronic-degenerative diseases of aging, including neurodegeneration.

In particular, the role of nitrotyrosylation in pathogenic mechanisms seems to occur not only in neurodegenerative disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS), but also in ischemic stroke, and inflammatory and autoimmune demyelinating diseases, particularly multiple sclerosis (MS) (Kochman et al., 2002). This review will be focused on the evidence available until now from experimental models and patients affected.

Parkinson's Disease (PD)

PD results from degeneration of dopaminergic neurons in the substantia nigra. There is considerable evidence that oxidative stress is associated with the progression of sporadic PD and may be an early stage in its progression (Sian et al., 1994; Beal, 2002; Jenner and Olanow, 1998). One of the mechanisms of oxidative dopaminergic cell injury is the nitration of protein residues mediated by PN, the reaction product of NO and superoxide radicals. In particular, formation of RNS such as PN has been implicated in apoptotic dopaminergic cell death in PD (Beal, 2002).

The presence of nitrotyrosine immunoreactivity has been demonstrated in Lewy bodies, which are a characteristic feature of PD and of dementia with Lewy body disease. This increased nitration of Tyr residues has been shown especially in the protein neurofilaments of the core (Good et al., 1998). This observation provides a definite link between oxidative stress and excitotoxicity within the vulnerable neurons of PD. Further evidence for the enhanced protein Tyr nitration in PD comes from studies showing that polymorphonuclear cells of PD patients exhibit an increase in rate of NO production that is accompanied by accumulation of nitrotyrosine-containing proteins together with an over-expression of neural nitric oxide synthase (nNOS) (Gatto et al., 2000).

In methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice elevated levels of DT and both bound and free 3-NT were found in the striatum and ventral midbrain

(Pennathur et al., 1999), lending additional support to the involvement of nitration of Tyr residues in PD.

It has also been demonstrated that the two neurotoxins, 1-methyl-4-phenylpyridinium (MPP⁺) and 6-hydroxydopamine, lead to Tyr nitration via tyrosine hydroxylase (TH) in cultured dopaminergic neurons (Pong et al., 2000). Nitration of Tyr residues is responsible for inactivation of TH, which is the rate-limiting enzyme in the synthesis of catecholamines with a consequent failure in the synthesis of dopamine. Nitrotyrosine formation on TH moieties seems to parallel the decrease of dopamine levels in the striatum and this mechanism has also been proposed to explain the increased severity of PD (Ara et al., 1998). Tyr residues are also essential in monoamine oxidase (MAO) substrate and inhibitor specificity. Therefore, their nitration could affect dopamine and melanin metabolism (Geha et al., 2000).

The presence of mutated α -synuclein found in some cases of familial PD results in self-aggregates and accumulation of abnormal proteins in the cells to give insoluble deposits that cannot undergo proteolysis by the proteasomes (Polymeropoulos et al., 1997; Mezey et al., 1998). This increases the susceptibility to oxidative stress, which is reflected by decreased levels of glutathione (GSH) and increased levels of 8-hydroxyguanine (8-OHG), protein carbonyls, lipid peroxidation markers and also 3-NT. Paradoxically, these oxidant stress-related changes may further promote aggregation of α -synuclein (Hashimoto et al., 1999) and may facilitate enhancement of the susceptibility to other injuries, including the inhibition of complex I in mitochondria by the inhibitor MPP⁺, proteasome inhibition by lactacystin and protein kinase inhibition by staurosporine. This multi-level challenge to neuronal cells associated with oxidative damage has been reported to trigger apoptosis (Lee et al., 2001a).

Abnormal staining of α -synuclein is not specific for familial PD, but has also been found in neurofilament inclusions in multisystemic atrophy (Spillantini et al., 1998) and AD (Goedert et al., 1998), and this could contribute to the increased neuronal vulnerability in these pathological conditions.

Alzheimer's Disease (AD)

Cognitive decline and dementia are key features of AD that results from degeneration of neuronal function in specific brain regions.

AD brain exhibits region-specific patterns of amyloid deposition, neurofibrillar tangles accumulation and neuronal death. The limbic system and associated areas in the

neocortex show the most pronounced histopathological alterations in AD, whereas cortical somatosensory and cerebellar neurons are relatively unaffected. Experimental models of AD attempt to link disease progression with an inflammatory component combined with increased oxidative stress (Rogers et al., 1996).

Enhanced oxidative stress in the AD brain is manifested by increased protein carbonyl content, lipid and DNA oxidation products, and inactivation of sensitive enzymes (Smith et al., 1991; Balazs and Leon, 1994; Chen et al., 1994; Hensley et al., 1995; Lovell et al., 1995; Smith et al., 1996, 1997; Butterfield et al., 1997; Lyras et al., 1997; Sayre et al., 1997).

These oxidative events seem to appear early in the process of neurodegeneration in AD (Numomura et al., 2001). NO-derived species are significant contributors to the pathogenic mechanisms underlying AD. Affected neurons demonstrate indices of nitro-oxidative stress and immunoreactive NOS suggesting that NOS-modified neurons are implicated in AD (Williamson et al., 2002).

In a study by Hensley et al. (1998) carried out on specimens of AD brains, DT and 3-NT levels were consistently elevated in the hippocampus and neocortical regions, and in ventricular fluid (VF), reaching values five to eightfold greater than in the brain and VF of normal subjects. The PN scavenger uric acid was, on the contrary, reduced in the same areas.

In a study by Tohgi et al. (1999a), the 3-NT concentration and the 3-NT/tyrosine ratio were also increased (>sixfold) in the cerebrospinal fluid (CSF) of AD patients compared to age-matched controls without cognitive impairment. Moreover, there was a significant correlation between the higher levels of these markers and the decrease in cognitive function.

Neurofibrillar tangles and dysfunctional neurons frequently display high levels of 3-NT or other markers of nitrosative stress and immunoreactive NOS (Colton et al., 2002).

On the other hand, neuronal DNA damage without evidence of tangle formation is associated with up-regulation of 3-NT in AD (Su et al., 1997). Neurotoxicity of beta-amyloid (A β)-42, which accumulates extracellularly in senile plaques, has been well established. It is associated with a larger area of glial fibrillary acidic protein immunoreactivity and a greater density of reactive astrocytes than is A β -40 (Klein et al., 1999).

Immunohistochemical staining for markers of oxidative and nitrate stress, such as 8-hydroxydeoxyguanosine (8-OHdG) and 3-NT, is significantly more intense around A β -40.

Although a strict correlation between oxidation and inflammatory biomarkers has not been definitively established for the AD brain, the inflammation-like pattern of AD brain oxidation suggests that inflammatory events are involved. In particular, it is known that activation of microglia leads to the release of both superoxide and hydrogen peroxide and that in the presence of β -amyloid peptide or proinflammatory cytokines astroglia and microglia express inducible NOS (iNOS) and generate NO-derived species, including PN (Colton et al., 1994; Beckman et al., 1994; Goodwin et al., 1995; Li et al., 1996; Hensley et al., 1997).

In a recent study, Luth et al. (2002) observed a high expression of both iNOS and endothelial NOS (eNOS) in glial cells and astrocytes. This was accompanied by an aberrant expression of nNOS in affected areas exhibiting increased formation of 3-NT. This suggests that the increased expression of all NOS isoforms in astrocytes, glial cells and neurons contributes to the synthesis of PN. In view of the wide range of isoform-specific NOS inhibitors available in the near future for therapeutic use, the identification of the most important isoform responsible for the formation of NO-derived species, and particularly PN in AD, could be of exquisite relevance in treating AD.

Amyotrophic lateral sclerosis (ALS)

ALS is a neurodegenerative disease occurring in adulthood that is characterized by the progressive loss of motor neurons in the motor cortex, brainstem and spinal cord. This results in progressive muscular weakness and eventually death within 3–5 years from the onset (Wong et al., 1995). About 10% of ALS cases are familial (FALS) and at least 80 mutations of the gene encoding for the isoform 1 of the enzyme Cu/Zn-superoxide dismutase (SOD1) have been identified in 20% of ALS patients (particularly familial cases) (Brown, 1995; Aguirre et al., 1998).

The majority of the mutations identified in SOD1 protein are located outside the catalytic site of the enzyme with a variable effect on the superoxide-scavenging activity (Swingler et al., 1995). Over-expression of mutated Cu/Zn-SOD1 is responsible for ALS-like symptoms in transgenic mice (Gurney et al., 1994). In particular, transgenic mice that over-express G93A and G37R mutant SOD1 protein suffer severe loss of motor neurons (Ferrante et al., 1997a; Liu et al., 1999).

A recent immunohistochemical study carried out on transgenic mice with G93A mutant SOD1 gene showed, from the early symptomatic to the end stage, positive iNOS and 3-NT immunoreactivity in proliferated reactive astrocytes as well as somata of the anterior horn cells

(Sasaki et al., 2001). The contribution of reactive astrocytes to the death of motor neurons in ALS via peroxynitrite-dependent damage is also suggested by the finding that these cells respond to extracellular PN by developing morphologic characteristics resembling those of process-bearing cells displaying intense glial fibrillar acidic protein and iNOS immunoreactivity. This phenotypic change results in broad cytotoxicity for motor neurons and was largely prevented by either NOS inhibitors or peroxynitrite scavengers, but not by trophic factors. Neuronal death was associated with highly positive staining for activated caspase-3 and 3-NT (Cassina et al., 2002).

Furthermore, SOD with different FALS mutations generated hydroxyl radicals more readily than wild-type SOD1 (Wiedau-Pazos et al., 1996; Yim et al., 1996).

Even in *in vitro* experiments, mutant SOD1 accelerates cell death (apoptosis), whereas expression of wild-type SOD1 protein protects cells against oxidative stress insults including protein Tyr nitrosylation (Ghadge et al., 1997; Rabizadeh et al., 1995). The effect of mutant SOD1 seems to be attenuated by the antioxidant-related and anti-apoptotic product of the oncogene Bcl-2 (Lee et al., 2001b).

Several lines of evidence suggest that oxidative stress is involved in the pathophysiology of ALS. They include reduced levels of GSH and increased levels of oxidative damage products such as protein carbonyls, 8-OHdG and 4-hydroxy-2-*trans*-nonenal (HNE) (Lanius et al., 1993; Shaw et al., 1995; Ferrante et al., 1997b; Hall et al., 1998; Pedersen et al., 1998). In ALS the attack of RNS on protein has been confirmed by the finding of increased levels of 3-NT in autaptic cases of both FALS and sporadic ALS (SALS) (Abe et al., 1997; Halliwell, 1997; Beal et al., 1997; Crow et al., 1997). A study carried out by Tohgi et al. (1999b) provided *in vivo* evidence for increased nitration of Tyr residues in patients with SALS, which is in line with previous findings of PN together with stable NO metabolites, i.e., nitrates and nitrites, in the CSF (Tohgi et al., 1999c; Shaw e Williams, 2000). As free Tyr concentrations in patients with SALS were not reduced, the increase in 3-NT in the CSF has been attributed to both an increase in nitrated Tyr in proteins and increased degradation of 3-NT-containing proteins, these being highly vulnerable to proteolytic degradation.

Nevertheless, results of other studies indicate that tyrosine nitration is not a major factor in the toxicity of G93A mutant SOD1. In a primary cell culture model, the prevention of 3-NT formation by inhibiting NOS rescued motor neurons from excitotoxic death but did not delay the death of motor neurons expressing G93A mutant SOD1 (Doroudchi et al., 2001).

The mechanisms by which PN selectively mediates motor neuron death in SALS, in which mutation-related gain of function of the SOD gene is not usually found, remain to be established.

Stroke

NO and oxygen free radicals have been proposed to be involved in the cascade of injury elicited by ischemia and reperfusion-mediated brain injury. Superoxide generation is augmented by ischemia reperfusion injury (Forman et al., 1998) and also a greater amount of NO is produced (Bidmon et al., 1998). Therefore, it is obvious that the brain expresses all the elements for the formation of PN in cytotoxic amounts, and consequently is an elective target tissue for NO-induced damage under stress conditions (Gürsoy-Ödzemir et al., 2000; Hirabayashi et al., 2000).

The involvement of NO release, derived from both up-regulation of constitutive and iNOS as well as nitrative injury, has been demonstrated in animal models of stroke.

In stroke-prone spontaneous hypertensive rats, endothelial dysfunction is associated with increased staining for 3-NT in vessels, and this can be attenuated by antioxidant treatment (Ma et al., 2001; Leker et al., 2002).

In the spontaneous stroke model immunohistochemical staining of 3-NT was also detected around vessels and in neuronal cells of brain ischemic lesions. This was observed immediately following the fluctuation of serum NO(x) at the onset of stroke (Tabuchi et al., 2002).

Concurrent formation of PN with the expression of iNOS has been demonstrated in the penumbra of rat brain ischemic lesions during reperfusion following middle cerebral artery occlusion and also in human cerebral infarcts (Forster et al., 2001). The increased NOx levels observed in the circulation have been attributed to the over-expression of iNOS (Suzuki et al., 2002). It was postulated that nNOS contributes to PN formation observed in the cortex during the early phase of reperfusion (Rodrigo et al., 2001).

The clear relationship between nNOS over-expression and peroxynitrite production was established in a recent investigation of the effects of oxygen and glucose deprivation on the distribution of nNOS and iNOS and protein nitration in the rat cerebral cortex, in a model of global cerebral ischemia and reperfusion. In this study, cerebrocortical injury, as shown by diffusion magnetic resonance imaging (MRI) was accompanied by increasing morphological changes in the large type I interneurons expressing nNOS and by the appearance of nNOS in small type II neurons. This NOS isoform showed an initial increase

followed by a fall 6 hours after reperfusion. Inducible NOS immunoreactivity appeared in neurons, especially the pyramidal cells of layers IV–V after 4 hours of reperfusion with a concomitant increase in calcium-independent NOS activity. During reperfusion, immunoreactive 3-NT present in the nuclear regions and perinuclear cytoplasm in control animals showed a widespread increase with a concurrent time-dependent translocation to the cytoplasm and neural processes (Alonso et al., 2002). This immunohistochemical appearance concurs with a previous study using amino acid analysis showing an increase in total 3-NT in the brain after cerebral ischemia (Takizawa et al., 1999). N(G)-nitro-L-arginine methyl ester (L-NAME) administration antagonizes MRI changes and attenuates morphological abnormalities observed during reperfusion. This suggests that overproduction of NO, likely through peroxynitrite formation, may contribute to stroke-related cerebral injury. Under hyperglycemic conditions there was an early and concomitant increase in both superoxide and NO production, which can lead to peroxynitrite formation and therefore protein Tyr residue nitration, and thereby contributes to the damage in ischemic areas (Ste-Marie et al., 2001).

Demyelinating and inflammatory CNS diseases

The concentrations of ROS and RNS can increase dramatically under inflammation conditions. This can overwhelm the inherent antioxidant defenses within lesions, leading to cell death. Oligodendrocytes are more sensitive than glial cells and astrocytes to oxidative and nitrative stress due to their lower antioxidant capacity and their higher iron content (Smith et al., 1999). This results in preferential oligodendrocyte death and damage of myelin sheaths.

Results of studies in experimental models of allergic encephalomyelitis (EAE) and MS have provided strong evidence that an increase in peroxynitrite formation is associated with disease activity in the CNS (van der Veen et al., 1997; Cross et al., 1997).

When analyzed by immunohistochemical and *in situ* hybridization techniques, postmortem brain tissues of MS patients show an intense reactivity against iNOS mRNA and protein in reactive astrocytes, macrophages, and endothelial cells, and also against 3-NT, a putative footprint of peroxynitrite. Staining for 3-NT was not evident in chronic lesions in which only reactive astrocytes at the edge of the lesions were positive for iNOS (Liu et al., 2001). The close proximity of nitrotyrosine as well as iNOS immunoreactivity to the vessels may contribute to the blood-brain barrier (BBB) damage that is a cardinal feature of active MS lesions (De Groot et al., 1997; Oleszak et al., 1998).

Early reports focused on the possibility that increased NO production induced by proinflammatory cytokines IL-1 and IFN- γ is responsible for tissue injury. This possibility was based on the observations that RNS are toxic to oligodendrocytes, they stimulate axon demyelination, and also that NO inhibitors are protective against EAE development (Mitrovic et al., 1994; Dawson and Dawson, 1998; Smith et al., 1999; Zhao et al., 1996; Hooper et al., 1997; Okuda et al., 1998). However, recent findings have questioned the purely destructive role of NO. In particular, targeted deletion of the iNOS gene in mice enhanced their susceptibility to EAE and also specific iNOS inhibition was found to prolong the disease, supporting a putative role of NO as an immunosuppressive and anti-inflammatory molecule (Fenyk-Melody et al., 1998; Sahrbacher et al., 1998; O'Brien et al., 1999; Arnett et al., 2002). A potential explanation for the detrimental role of NO pathway activation is that NO per se is not responsible for myelin damage; rather, its downstream products such as PN could be the real damaging species (Willenborg et al., 1999). They are produced by the interaction between sensitized lymphocytes and activated macrophages/microglia as sources of proinflammatory cytokines and ROS, and by astrocytes that produce NO in response to cytokines. This hypothesis is consistent with data from EAE models, where there was widespread evidence of peroxynitrite formation in animals with active disease but not during disease recovery. Of great relevance in this regard are also the findings of Cross et al. (1998) who demonstrated the immunoreactivity for 3-NT in active lesions and the increase in nitrites and PN in the CSF of MS patients during a relapse. PN may lead not only to myelin disorganization but also to axonal damage and this can contribute to the permanent disability in MS patients (Touil et al., 2001). The increase in this marker of peroxynitrite production is not restricted to MS. Autopsy of CNS tissues from patients with AIDS-associated dementia complex showed an intense and widespread distribution of 3-NT, which was not evident in patients with HIV-associated encephalitis without dementia (Cross et al., 1997).

The CNS inflammatory response to neurotropic virus infection is also likely dependent on the activity of PN or its byproducts on the BBB (Hooper et al., 2001). Strategies aimed at antagonizing PN formation, such as the supplementation of ascorbic and uric acids, could therefore be potentially helpful, at least from a theoretical point of view, in maintaining BBB integrity, lessening CNS inflammation and destruction of target tissues in autoimmune and inflammatory diseases involving the CNS (Whiteman and Halliwell, 1996; Kean et al., 2000; Squadrito et al., 2000; Whiteman et al., 2002).

Table 1. Most relevant findings supporting nitrotyrosine formation in post-mortem brain tissues of patients affected by neurodegenerative diseases, stroke and Multiple Sclerosis

Disease (a)
Authors
Findings
Prevailing location
Comments
Parkinson's Disease
Affected areas
Good et al., 1998
Increased 3-NT immunoreactivity
Neurofilament proteins in Lewy body cores
This observation provides a potential link between excitotoxicity and oxidative stress
Alzheimer's Disease
Affected areas
Good et al., 1996
Increased 3-NT immunoreactivity
Neurofibrillary tangles
These findings link oxidative stress to NFT, and implicate NO expression and excitotoxicity in the pathogenesis of cell death in AD
Visual cortex
Su et al., 1997
Increased 3-NT expression
Terminal deoxynucleotidyl transferase neurons lacking evidence for tangle formation
Neurons with DNA damage in the absence of tangle formation may degenerate by tangle-independent mechanisms and oxidative stress may contribute to such mechanisms
Parkinson's Disease
Dementia with Lewy bodies, Lewy body variant of Alzheimer's Disease
Multiple system atrophy
Affected brain areas
Giasson et al., 2000
Widespread accumulation of nitrated alpha-synuclein
Major filamentous building blocks of signature inclusions
The selective and specific nitration of alpha-synuclein in these disorders provides evidence to directly link oxidative and nitrative damage to the onset and progression of neurodegenerative synucleinopathies
Amyotrophic lateral sclerosis
Sporadic form: spinal cord
Abe et al., 1995
Increased immunoreactivity for 3-NT
Anterior horn motor neurons
Contribution of peroxynitrite formation to motor neuron damage
Sporadic and familial form: lumbar and thoracic spinal cord
Beal et al., 1997
Increased immunoreactivity for 3-NT and 3-nitro-4-hydroxyphenylacetic acid
Motor neurons
Peroxyntirite-mediated oxidative damage may play a role in the pathogenesis of both sporadic and familial ALS
Sporadic form: spinal cord
Abe et al., 1997
Increased immunoreactivity for nNOS, eNOS, 3-NT

Table 1 (continued)

Anterior horn motor neurons
The nitration of protein-Tyr residues is upregulated in motor neurons of the spinal cord with selective increase of brain and endothelial NOS-like immunoreactivities
Sporadic form: cervical spinal cord
Strong et al., 1998
3-NT immunoreactivity
Neurofilament subunit protein (NFL)
NFL is particularly susceptible to peroxynitrite-mediated damage
Ischemic Stroke
Autopsied brain ischemic stroke tissue
Forster et al., 1999
iNOS and 3-NT immunoreactivity
Neutrophils infiltrating the ischemic brain and in blood vessels within the ischemic territory
The evidence of NO production and peroxynitration support the hypothesis that iNOS inhibitors may be useful in the treatment of stroke
Multiple Sclerosis
Autopsied brain tissues
Severe form
Bagasra et al., 1995
Detectable iNOS
nitrotyrosine
Monocyte/macrophages
iNOS is expressed at significant levels in the brains of patients with MS and may contribute to the pathology associated with the disease
Autopsied brain tissues
Severe form
Van der Veen et al., 1997
Nitrotyrosine staining
CD11b-positive cells (macrophages/microglia)
PN is formed during progressive stages of disease activity
Autopsied brain tissues
Cross et al., 1998
3-NT detected immunohistochemically
MS sections displaying inflammation
PN-mediated damage of CNS is associated with disease activity
Autopsied brain tissues
Liu et al., 2001
Intense reactivity for iNOS staining for 3-NT
(iNOS) reactive astrocytes in active lesions and edges of chronic lesions, Macrophages, inflammatory cells and endothelial cells in active lesions, 3-NT in acute but not chronic lesions, displayed a diffuse parenchymal membranous and perivascular pattern
NO-mediated and peroxynitrite formation during the active phase and can concur in oligodendrocyte damage

(a): Brain areas from which the autopsied specimens were taken are specified, as reported by the Authors

Conclusion

The involvement of nitrative oxidation has been clearly demonstrated both in neurodegenerative and inflammatory disorders of the CNS. Nitrative oxidation is also

Table 2. Evidence for the production of nitrotyrosine in the CSF of patients affected by Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis

	Authors	Findings	Comments
Alzheimer's Disease			
	Teunissen et al., 2002	Increase in 3-NT, 8-OHdG, isoprostanes	Increase in nitrative and oxidative stress markers
Amyotrophic lateral sclerosis			
Sporadic	Tohgi et al., 1999c	Sevenfold increase of 3-NT and 3-NT/Tyr compared with controls	These data provide <i>in vivo</i> evidence for a possible role of peroxynitrites, a mediator of oxidative stress, and increased nitration of Tyr residues in the pathogenesis of sporadic ALS
Sporadic	Shaw & Williams, 2000	Increase of 3-NT and neurofilament light in CSF	These parameters, while not entirely disease-specific for ALS, may nevertheless be confirmatory markers of the disease and its progression
Not specified	Aoyama et al., 2000	Increased nitrated Mn-SOD	Slight increase also in Alzheimer's disease and Parkinson's disease
Multiple Sclerosis			
	Calabrese et al., 2002	iNOS was detected by Western blot Increase in NOS activity Greatly increased nitrotyrosine immunostaining of CSF proteins	These data strongly support a role for nitrosative stress in the pathogenesis of MS and indicate that therapeutic strategies focussed on decreasing production of NO by iNOS and/or scavenging peroxynitrite may be useful in alleviating the neurological impairments occurring during relapse

one of the mechanisms that contributes to the ischemic injury, particularly during the reperfusion phase.

The role played by RNS formation in the sequential pathophysiological mechanisms of brain damage in these pathologies remains to be established. The majority of studies comes from animal models and postmortem samples (Table 1). A few studies have been carried out *in vivo*, especially in the CSF, and longitudinal evaluation of the markers of peroxidation are lacking (Table 2).

Efforts should be made to verify the relevance of assessing peroxidation markers in relationship to patient outcome, particularly in light of a detailed identification of targeted and well-timed therapeutic strategies.

Acknowledgements

The authors express their gratitude to John A. Toomey for editing the English and Marisa M. Morson for technical assistance

References

- Abe K, Pan LH, Watanabe M, Kato T, Itoyama Y (1995) Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. *Neurosci Lett* 199: 152–154
- Abe K, Pan LH, Watanabe M, Konno H, Kato T, Itoyama Y (1997) Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. *Neurol Res* 19: 124–128
- Aguirre T, Van Den Bosch L, Goetschalckx K, Tilkin P, Mathijs G, Cassiman JJ, Robberecht W (1998) Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. *Ann Neurol* 43: 452–457
- Alonso D, Serrano J, Rodriguez I, Ruiz-Cabello J, Fernandez AP, Encinas JM, Castro-Blanco S, Bentura ML, Santacana M, Richart A, Fernandez-Vizarra P, Uttenthal LO, Rodrigo J (2002) Effects of oxygen and glucose deprivation on the expression and distribution of neuronal and inducible nitric oxide synthases and on protein nitration in rat cerebral cortex. *J Comp Neurol* 443: 183–200
- Aoyama K, Matsubara K, Fujikawa Y, Nagahiro Y, Shimizu K, Umegae N, Hayase N, Shiono H, Kobayashi S (2000) Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. *Ann Neurol* 47: 524–527
- Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). *Proc Natl Acad Sci USA* 95: 7659–7663
- Arnett HA, Hellendall RP, Matsushima GK, Suzuki K, Laubach VE, Sherman P, Ting JP (2002) The protective role of nitric oxide in a neurotoxicant-induced demyelinating model. *J Immunol* 168: 427–433
- Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H (1995) Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. *Proc Natl Acad Sci USA* 92: 12041–12045
- Balazs L, Leon M (1994) Evidence of an oxidative challenge in the Alzheimer's brain. *Neurochem Res* 19: 1131–1137
- Beal MF (2002) Oxidatively modified proteins in aging and disease. *Free Radic Biol Med* 32: 797–803
- Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. *Ann Neurol* 42: 644–654
- Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol* 271: C1424–C1437
- Beckman JS, Chen J, Ischiropoulos H, Crow JP (1994) Oxidative chemistry of peroxynitrite. *Methods Enzymol* 233: 229–240

- Bidmon HJ, Wu J, Buchkremer-Ratzmann I, Mayer B, Witte OW, Zilles K (1998) Transient changes in the presence of nitric oxide synthases and nitrotyrosine immunoreactivity after focal cortical lesions. *Neuroscience* 82: 377–395
- Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, Lee SC (1994) Reactive nitrogen intermediates in human neuropathology: an overview. *Dev Neurosci* 16: 152–161
- Brown RH Jr (1995) Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. *Cell* 80: 687–692
- Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, Carney JM (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. *J Neurochem* 68: 2451–2457
- Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates T, Giuffrida Stella AM, Pennisi G (2002) Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. *J Neurosci Res* 70: 580–587
- Cassina P, Peluffo H, Pehar M, Martinez-Palma L, Ressler A, Beckman JS, Estevez AG, Barbeito L (2002) Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. *J Neurosci Res* 67: 21–29
- Chen L, Richardson JS, Caldwell JE, Ang LC (1994) Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. *Int J Neurosci* 75: 83–90
- Colton CA, Snell J, Chernyshev O, Gilbert DL (1994) Induction of superoxide anion and nitric oxide production in cultured microglia. *Ann NY Acad Sci* 738: 54–63
- Colton CA, Brown CM, Czapiga M, Vitek MP (2002) Apolipoprotein-E allele-specific regulation of nitric oxide production. *Ann NY Acad Sci* 962: 212–225
- Cross AH, Manning PT, Stern MK, Misko TP (1997) Evidence for the production of peroxynitrite in inflammatory CNS demyelination. *J Neuroimmunol* 80: 121–130
- Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP (1998) Peroxynitrite formation within the central nervous system in active multiple sclerosis. *J Neuroimmunol* 88: 45–56
- Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS (1997) Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. *J Neurochem* 69: 1936–1944
- Dawson VL, Dawson TM (1998) Nitric oxide in neurodegeneration. *Prog Brain Res* 118: 215–229
- De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P (1997) Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. *J Neuropathol Exp Neurol* 56: 10–20
- Doroudchi MM, Minotti S, Figlewicz DA, Durham HD (2001) Nitrotyrosination contributes minimally to toxicity of mutant SOD1 associated with ALS. *Neuroreport* 12: 1239–1243
- Fenyk-Melody JE, Garrison AE, Brunnert SR, Weidner JR, Shen F, Shelton BA, Mudgett JS (1998) Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. *J Immunol* 160: 2940–2946
- Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, Beal MF (1997a) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. *Ann Neurol* 42: 326–334
- Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, Beal MF (1997b) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. *J Neurochem* 69: 2064–2074
- Forman LJ, Liu P, Nagele RG, Yin K, Wong PY (1998) Augmentation of nitric oxide, superoxide, and peroxynitrite production during cerebral ischemia and reperfusion in the rat. *Neurochem Res* 23: 141–148
- Forster C, Clark HB, Ross ME, Iadecola C (1999) Inducible nitric oxide synthase expression in human cerebral infarcts. *Acta Neuropathol (Berl)* 97: 215–220
- Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML, Poderoso JJ (2000) Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. *Nitric Oxide* 4: 534–539
- Geha RM, Chen K, Shih JC (2000) Phe (208) and Ile (199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat. *J Neurochem* 75: 1304–1309
- Ghadge GD, Lee JP, Bindokas VP, Jordan J, Ma L, Miller RJ, Roos RP (1997) Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. *J Neurosci* 17: 8756–8766
- Giascon BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. *Science* 290: 985–989
- Goedert M, Jakes R, Crowther RA, Hasegawa M, Smith MJ, Spillantini MG (1998) Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. *Biochem Soc Trans* 26: 463–471
- Good PF, Werner P, Hsu A, Olanow CW, Perl DP (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. *Am J Pathol* 149: 21–28
- Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson's disease. *J Neuropathol Exp Neurol* 57: 338–342
- Goodwin JL, Uemura E, Cunnick JE (1995) Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. *Brain Res* 692: 207–214
- Gracy RW, Talent JM, Kong Y, Conrad CC (1999) Reactive oxygen species: the unavoidable environmental insult? *Mutat Res* 428: 17–22
- Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. *Science* 264: 1772–1775
- Gürsoy-Özdemir Y, Bolay H, Saribas O, Dalkara T (2000) Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. *Stroke* 31: 1974–1980
- Hall ED, Andrus PK, Oostveen JA, Fleck TJ, Gurney ME (1998) Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. *J Neurosci Res* 53: 66–77
- Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation *in vivo*? *FEBS Lett* 411: 157–160
- Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein *in vitro*. *Neuroreport* 10: 717–721
- Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, et al (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. *J Neurochem* 65: 2146–2156
- Hensley K, Maidt ML, Pye QN, Stewart CA, Wack M, Tabatabaie T, Floyd RA (1997) Quantitation of protein-bound 3-nitrotyrosine and 3,4-dihydroxyphenylalanine by high-performance liquid chromatography with electrochemical array detection. *Anal Biochem* 251: 187–195
- Hensley K, Maidt ML, Zhenqiang Y, Sang H, Markesbery WR, Floyd RA (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. *J Neurosci* 18: 8126–8132
- Hirabayashi H, Takizawa S, Fukuyama N, Nakazawa H, Shinohara Y (2000) Nitrotyrosine generation via inducible nitric oxide synthase in vascular wall in focal ischemia-reperfusion. *Brain Res* 852: 319–325

- Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, Koprowski H (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. *Proc Natl Acad Sci USA* 94: 2528–2533
- Hooper DC, Kean RB, Scott GS, Spitsin SV, Mikheeva T, Morimoto K, Bette M, Röhrenbeck AM, Dietzschold B, Weihe E (2001) The central nervous system inflammatory response to neurotropic virus infection is peroxynitrite dependent. *J Immunol* 167: 3470–3477
- Ii M, Sunamoto M, Ohnishi K, Ichimori Y (1996) Beta-amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. *Brain Res* 720: 93–100
- Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. *Ann Neurol* 44 [3 Suppl 1]: S72–S84
- Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC (2000) The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. *J Immunol* 165: 6511–6518
- Klein AM, Kowall NW, Ferrante RJ (1999) Neurotoxicity and oxidative damage of beta amyloid 1–42 versus beta amyloid 1–40 in the mouse cerebral cortex. *Ann NY Acad Sci* 893: 314–320
- Kochman A, Koska Cz, Metodiewa D (2002) Submolecular adventures of brain tyrosine: what are we searching for now? *Amino Acids* 23: 95–101
- Lanius RA, Krieger C, Wagey R, Shaw CA (1993) Increased [35S] glutathione binding sites in spinal cords from patients with sporadic amyotrophic lateral sclerosis. *Neurosci Lett* 163: 89–92
- Lee M, Hyun D, Halliwell B, Jenner P (2001a) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. *J Neurochem* 76: 998–1009
- Lee M, Hyun D, Halliwell B, Jenner P (2001b) Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative stress and cell death induced by hydrogen peroxide, 4-hydroxynonenal or serum deprivation: potentiation of injury by ALS-related mutant superoxide dismutases and protection by Bcl-2. *J Neurochem* 78: 209–220
- Leker RR, Teichner A, Lavie G, Shohami E, Lamensdorf I, Ovadia H (2002) The nitroxide antioxidant tempol is cerebroprotective against focal cerebral ischemia in spontaneously hypertensive rats. *Exp Neurol* 176: 355–363
- Liu D, Wen J, Liu J, Li L (1999) The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. *FASEB J* 13: 2318–2328
- Liu JS, Zhao ML, Brosnan CF, Lee SC (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. *Am J Pathol* 158: 2057–2066
- Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. *Neurology* 45: 1594–1601
- Luth H, Munch G, Arendt T (2002) Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. *Brain Res* 953: 135–143
- Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. *J Neurochem* 68: 2061–2069
- Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC (2001) Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. *J Pharmacol Exp Ther* 298: 879–885
- Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ (1998) Alpha-synuclein in neurodegenerative disorders: murderer or accomplice? *Nat Med* 4: 755–757
- Mitrovic B, Ignarro LJ, Montestrucque S, Smoll A, Merrill JE (1994) Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells *in vitro*. *Neuroscience* 61: 575–585
- Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jon PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer's disease. *J Neuropathol Exp Neurol* 60: 759–767
- O'Brien NC, Charlton B, Cowden WB, Willenborg DO (1999) Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction. *J Immunol* 163: 6841–6847
- Okuda Y, Sakoda S, Fujimura H, Yanagihara T (1998) Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experimental allergic encephalomyelitis in the induction and progression phase. *J Neuroimmunol* 81: 201–210
- Oleszak EL, Zaczynska E, Bhattacharjee M, Butunoi C, Legido A, Katsetos CD (1998) Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. *Clin Diagn Lab Immunol* 5: 438–445
- Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, Mattson MP (1998) Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. *Ann Neurol* 44: 819–824
- Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW (1999) Mass spectrometric quantification of 3-nitrotyrosine, *ortho*-tyrosine, and *o,o'*-dityrosine in brain tissue of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. *J Biol Chem* 274: 34621–34628
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276: 2045–2047
- Pong K, Doctrow SR, Baudry M (2000) Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons. *Brain Res* 881: 182–189
- Rabizadeh S, Gralla EB, Borchelt DR, Gwinn R, Valentine JS, Sisodia S, Wong P, Lee M, Hahn H, Bredesen DE (1995) Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. *Proc Natl Acad Sci USA* 92: 3024–3028
- Rodrigo J, Alonso D, Fernandez AP, Serrano J, Richart A, Lopez JC, Santacana M, Martinez-Murillo R, Bentura ML, Ghiglion M, Uttenthal LO (2001) Neuronal and inducible nitric oxide synthase expression and protein nitration in rat cerebellum after oxygen and glucose deprivation. *Brain Res* 909: 20–45
- Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P (1996) Inflammation and Alzheimer's disease pathogenesis. *Neurobiol Aging* 17: 681–686
- Sahrbacher UC, Lechner F, Eugster HP, Frei K, Lassmann H, Fontana A (1998) Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. *Eur J Immunol* 28: 1332–1338
- Sasaki S, Warita H, Abe K, Iwata M (2001) Inducible nitric oxide synthase (iNOS) and nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with a G93A mutant SOD1 gene. *J Neuropathol Exp Neurol* 60: 839–846
- Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. *J Neurochem* 68: 2092–2097
- Shaw PJ, Ince PG, Falkous G, Mantle D (1995) Oxidative damage to protein in sporadic motor neuron disease spinal cord. *Ann Neurol* 38: 691–695

- Shaw PJ, Williams R (2000) Serum and cerebrospinal fluid biochemical markers of ALS. *Amyotroph Lateral Scler Other Motor Neuron Disord* [1 Suppl 2]: S61–S67
- Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson's disease. *Ann Neurol* 36: 356–361
- Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. *Proc Natl Acad Sci USA* 88: 10540–10543
- Smith KJ, Kapoor R, Felts PA (1999) Demyelination: the role of reactive oxygen and nitrogen species. *Brain Pathol* 9: 69–92
- Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. *Nature* 382: 120–121
- Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. *J Neurosci* 17: 2653–2657
- Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett* 251: 205–208
- Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA (2000) Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. *Arch Biochem Biophys* 376: 333–337
- Ste-Marie L, Hazell AS, Bemeur C, Butterworth R, Montgomery J (2001) Immunohistochemical detection of inducible nitric oxide synthase, nitrotyrosine and manganese superoxide dismutase following hyperglycemic focal cerebral ischemia. *Brain Res* 918: 10–19
- Strong MJ, Sopper MM, Crow JP, Strong WL, Beckman JS (1998) Nitration of the low molecular weight neurofilament is equivalent in sporadic amyotrophic lateral sclerosis and control cervical spinal cord. *Biochem Biophys Res Commun* 248: 157–164
- Su JH, Deng G, Cotman CW (1997) Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain. *Brain Res* 774: 193–199
- Suzuki M, Tabuchi M, Ikeda M, Tomita T (2002) Concurrent formation of peroxynitrite with the expression of inducible nitric oxide synthase in the brain during middle cerebral artery occlusion and reperfusion in rats. *Brain Res* 951: 113–120
- Swingler RJ, Jones C, Brock DJ (1995) Superoxide dismutase and amyotrophic lateral sclerosis. *Lancet* 345: 391–392
- Tabuchi M, Umegaki K, Ito T, Suzuki M, Tomita I, Ikeda M, Tomita T (2002) Fluctuation of serum NO(x) concentration at stroke onset in a rat spontaneous stroke model (M-SHRSP). Peroxynitrite formation in brain lesions. *Brain Res* 949: 147–156
- Takizawa S, Fukuyama N, Hirabayashi H, Nakazawa H, Shinohara Y (1999) Dynamics of nitrotyrosine formation and decay in rat brain during focal ischemia-reperfusion. *J Cereb Blood Flow Metab* 19: 667–672
- Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C (2002) Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. *Neurobiol Aging* 23: 485–508
- Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999a) Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. *Neurosci Lett* 269: 52–54
- Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999b) Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. *Neurosci Lett* 260: 204–206
- Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999c) Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. *Ann Neurol* 46: 129–131
- Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) *In vivo* damage of CNS myelin and axons induced by peroxynitrite. *Neuroreport* 12: 3637–3644
- Van der Veen RC, Hinton DR, Incardonna F, Hofman FM (1997) Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. *J Neuroimmunol* 77: 1–7
- Van der Vliet A, Eiserich JP, O'Neill CA, Halliwell B, Cross CE (1995) Tyrosine modification by reactive nitrogen species: a closer look. *Arch Biochem Biophys* 319: 341–349
- Whiteman M, Halliwell B (1996) Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by ascorbic acid. A comparison with other biological antioxidants. *Free Radic Res* 25: 275–283
- Whiteman M, Ketsawatsakul U, Halliwell B (2002) A reassessment of the peroxynitrite scavenging activity of uric acid. *Ann N Y Acad Sci* 962: 242–259
- Wiedau-Pazos M, Goto JJ, Rabizadeh S, Gralla EB, Roe JA, Lee MK, Valentine JS, Bredesen DE (1996) Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. *Science* 271: 515–518
- Willenborg DO, Staykova MA, Cowden WB (1999) Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review. *J Neuroimmunol* 100: 21–35
- Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, Cooney RV, Grammas P, Reimann-Philipp U, Floyd RA, Hensley K (2002) The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. *Nitric Oxide* 6: 221–227
- Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. *Neuron* 14: 1105–1116
- Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER (1996) A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in K_m for hydrogen peroxide. *Proc Natl Acad Sci USA* 93: 5709–5714
- Zhang H, Joseph J, Felix C, Kalyanaraman B (2000) Bicarbonate enhances the hydroxylation, nitration, and peroxidation reactions catalyzed by copper, zinc superoxide dismutase. Intermediacy of carbonate anion radical. *J Biol Chem* 275: 14038–14045
- Zhao W, Tilton RG, Corbett JA, McDaniel ML, Misko TP, Williamson JR, Cross AH, Hickey WF (1996) Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. *J Neuroimmunol* 64: 123–133

Authors' address: Paola Sarchielli, Neurological Clinic, Neuroscience Department, University of Perugia, Via E. Dal Pozzo, 06126 Perugia, Italy, Fax: 0039/075/578-3583, E-mail: neuro.pg@tiscalinet-it, neuro@netemedia.net